Details of the Drug-Related molecule(s) Expression Atlas
General Information of Drug (ID: DM7CNTG)
Drug Name | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
UNII-BO0V7196L2; BO0V7196L2; Murizatoclax; Murizatoclax [USAN]; SCHEMBL21040009; WHO 11281; (13S,31R,32R,4R,5E,8S,9R)-6'-Chloro-4-methoxy-8,9-dimethyl-4-(((9aR)-octahydro-2H-pyrido(1,2-a)pyrazin-2-yl)methyl)-3',4'-dihydro-12H,14H,2'Hspiro(10lambda6-thia-11-aza-1(5,7)-(1,5)benzoxazepina-3(1,2)-cyclobutanacyclododecaphan-5-ene-13,1'-naphthalene)-10,10,12-trione; 2245848-05-7; Spiro(5,7-etheno-1H,11H-cyclobut(i)(1,4)oxazepino(3,4-f)(1,2,7)thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen)-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-16-(((9aR)-octahydro-2H-pyrido(1,2-a)pyrazin-2-yl)methyl)-, 10,10-dioxide, (1'S,11R,12S,14E,16R,16aR,18aR)-
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecule(s) Related to This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs
|
||||||||||||||||||||||||||
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue
The Studied Disease | Refractory hematologic malignancy | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | 2A85.5 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue | ||||||||||||||||||||||||